IMWG	International Myeloma Working Group
MRD	minimal residual disease
NGF	next-generation flow
NGS	next-generation sequencing
FLC	free light chain
M-protein	myeloma protein
FCM	flow cytometry
SUVmax	maximum standardized uptake value
MFC	multiparameter flow cytometry
FDG	Fluorodeoxyglucose
PET/CT	Positron emission tomography/computed tomography
N	number
TTP	time to progression
y	year
NR	not reached
CA	chromosomal abnormalities
PCs	plasma cells
BMPCs	bone marrow PCs
HR	hazard ratio
FLCr	free light chain ratio
FISH	fluorescence in situ hybridization
Pts	patients
V	bortezomib
R, Len	lenalidomide
d, dex	dexamethasone
T	thalidomide
FU	follow-up
PFS	progression-free survival
OS	overall survival
G	grade
P	p-value
MM	multiple myeloma
K	carfilzomib
CRAB	hypercalcemia, renal failure, anemia, and bone lesions
SMM	smoldering MM
ORR	overall response rate
Dara	daratumumab
ASCT	autologous stem-cell transplantation
Y	years
NA	not available
iv	intravenous
D	day
AE	adverse event
sc	subcutaneous
p.o.	orally
G-CSF	granulocyte colony-stimulating factor
Obs.	observation
TE	Transplant-eligible
NTE	non-transplant-eligible
NDMM	newly diagnosed multiple myeloma
C	cyclophosphamide
PD	progressive disease
MR	minimal response
PR	partial response
VGPR	very good PR
CR	complete response
nCR	near CR
sCR	stringent CR
CHF	congestive heart failure
SPMs	second primary malignancies
MRD neg	MRD negative/negativity
M, Mel	melphalan
Mel200	melphalan at 200 mg/m2
Bu	busulfan
p	prednisone
Ixa	ixazomib
SAEs	serious AEs
TEAEs	treatment-emergent AEs
GIT	gastrointestinal toxicity
QW	given every week
Q2W	given every two weeks
Q4W	given every 4 weeks
CI	confidence interval
ISS	International Staging System
R-ISS	Revised ISS
LDH	lactate dehydrogenase
EMD	extramedullary disease
CPC	circulating plasma cells
mAb	monoclonal antibody
PI	proteasome inhibitor
IMiDs	immunomodulatory drugs